PKP2 and lung carcinoma: Research suggests that the PRMT1 inhibitor C‐7280948 may enhance the radiosensitivity of lung cancer by modulating the PRMT1/PKP2/β‐catenin/LIG4 signaling pathway, thereby overcoming radiation resistance and improving patient outcomes [99].